Celldex Therapeutics, Inc.

What they do

Celldex is focused on mast cell biology and develops monoclonal and bispecific antibodies for severe inflammatory, allergic and autoimmune diseases where available treatments are inadequate. Its lead candidate, barzolvolimab (CDX-0159), is a monoclonal antibody that binds the KIT receptor and inhibits its activity, and is in Phase 3 development in chronic spontaneous urticaria (CSU), cold urticaria (ColdU) and symptomatic dermographism (SD). The company is also developing CDX-622, a bispecific antibody targeting TSLP and SCF, in Phase 1. Celldex has no approved products and reports only minimal collaboration and grant revenue.

Revenue drivers

• Collaboration and grant revenue — Nearly all revenue is non-product collaboration, license and grant revenue; annual revenue was $1.5M in 2025, down from $7.0M in 2024, and quarterly revenue was just $22,000 in the quarter ended June 30, 2026.
• Barzolvolimab (CDX-0159) — Pre-commercial KIT-inhibitor antibody in Phase 3 for CSU (EMBARQ-CSU1 and EMBARQ-CSU2) and Phase 3 for ColdU/SD; no product revenue is generated today, and a BLA filing in CSU is planned for 2027.
• CDX-622 (TSLP & SCF bispecific) — Phase 1 bispecific candidate for inflammatory diseases; no revenue today. A Phase 1a study in healthy volunteers completed enrollment in January 2026 and a Phase 1 proof-of-mechanism asthma study is ongoing.

Recent performance

Celldex reported no product revenue; quarterly revenue was $15,000 in Q1 2026 and $22,000 in Q2 2026, versus $695,000 and $730,000 in the first two quarters of 2025. Full-year 2025 revenue was $1.5M and the net loss was $258.8M, compared with $7.0M of revenue and a $157.9M net loss in 2024. Operating cash use was $210.9M in 2025. At June 30, 2026, the company reported total assets of $782.3M, total liabilities of $67.8M, shareholder equity of $714.6M and cash and equivalents of $47.5M. In July 2026, the company reported that the Phase 2 prurigo nodularis (PN) study did not meet primary or key secondary endpoints.

Strategy

The company's stated mission is to become a fully integrated, commercial-stage biopharmaceutical company, and it says it may retain full economic rights to its therapies or seek commercial partnerships. Near-term priorities are completing the Phase 3 CSU program and preparing a planned BLA filing in 2027, advancing the Phase 3 ColdU/SD study, and reporting Phase 2 AD topline data in late 2026. It is also developing its bispecific antibody platform, including CDX-622, with Phase 1 multiple-ascending-dose and subcutaneous data anticipated in the third quarter of 2026. Management describes the pipeline as targeting inflammatory diseases where mast cells are implicated, with barzolvolimab followed by CDX-622.

Risks

• Need for additional capital — The company cites risks related to its need for additional capital to fund operations, and if it cannot raise funds it may have to delay or discontinue programs or trials.
• Clinical and regulatory failure — Its product candidates are still in development, and in July 2026 the Phase 2 PN study missed primary and key secondary endpoints, illustrating the risk that trials may not succeed.
• No approved products or commercial infrastructure — Celldex has no approved drug candidates and faces risks related to delays or unanticipated costs in establishing sales, marketing and distribution capabilities.
• Competition and reimbursement — The company cites risks in showing its drug candidates are effective and competitive with other therapies, and risks related to third-party payor reimbursement decisions and physician, patient and payor acceptance.

Outlook

Management says topline data from the two Phase 3 CSU trials (EMBARQ-CSU1 and EMBARQ-CSU2), which enrolled 1,939 patients, are anticipated in September/October 2026 and support a planned BLA filing in 2027. Phase 2 topline data in atopic dermatitis are expected in late 2026, and the Phase 3 ColdU/SD study is actively enrolling. CDX-622 multiple-ascending-dose and subcutaneous data are anticipated in the third quarter of 2026, with a Phase 1 proof-of-mechanism asthma study ongoing.